B
30.70
0.00 (0.00%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Bearish |
Biotechnology (Global) | Mixed | Bearish | |
Stock | BridgeBio Pharma, Inc. | Bearish | Mixed |
Stockmoo Score
1.4
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Growth |
Ownership
Name | Date | Shares Held |
---|---|---|
Kohlberg Kravis Roberts & Co. L.P. | 30 Jun 2024 | 31,060,971 |
Aisling Capital Management Lp | 30 Jun 2024 | 6,068,125 |
Laurion Capital Management Lp | 30 Jun 2024 | 4,388,873 |
52 Weeks Range | ||
Price Target Range | ||
High | 70.00 (Cantor Fitzgerald, 128.01%) | Buy |
Median | 44.50 (44.95%) | |
Low | 42.00 (B of A Securities, 36.81%) | Buy |
Average | 50.25 (63.68%) | |
Total | 4 Buy | |
Avg. Price @ Call | 28.37 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Cantor Fitzgerald | 09 Sep 2024 | 70.00 (128.01%) | Buy | 30.70 |
01 Jul 2024 | 70.00 (128.01%) | Buy | 25.20 | |
Piper Sandler | 04 Sep 2024 | 46.00 (49.84%) | Buy | 30.67 |
HC Wainwright & Co. | 03 Sep 2024 | 43.00 (40.07%) | Buy | 28.74 |
27 Aug 2024 | 43.00 (40.07%) | Buy | 24.98 | |
B of A Securities | 25 Jun 2024 | 42.00 (36.81%) | Buy | 23.38 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |